Pyxis Oncology, Inc. - PYXS

Ownership (Schedule 13D / 13G) · latest 50 filings · Back to all files
Visible: 0
Filed Form Reporting person Percent Shares SEC
Jul 10, 2026 SCHEDULE 13G BIOTECHNOLOGY VALUE FUND L P 5.5% 4,611,887 View
Jul 10, 2026 SCHEDULE 13G BVF I GP LLC 5.5% 4,611,887 View
Jul 10, 2026 SCHEDULE 13G BIOTECHNOLOGY VALUE FUND II LP 3.7% 3,083,847 View
Jul 10, 2026 SCHEDULE 13G BVF II GP LLC 3.7% 3,083,847 View
Jul 10, 2026 SCHEDULE 13G Biotechnology Value Trading Fund OS LP 0.6% 518,280 View
Jul 10, 2026 SCHEDULE 13G BVF Partners OS Ltd. 0.6% 518,280 View
Jul 10, 2026 SCHEDULE 13G BVF GP HOLDINGS LLC 9.2% 7,695,734 View
Jul 10, 2026 SCHEDULE 13G BVF PARTNERS L P/IL 9.99% 8,336,902 View
Jul 10, 2026 SCHEDULE 13G BVF INC/IL 9.99% 8,336,902 View
Jul 10, 2026 SCHEDULE 13G LAMPERT MARK N 9.99% 8,336,902 View
Jul 02, 2026 SCHEDULE 13G/A GordonMD Global Investments LP 12.1% 10,024,909 View
Jul 02, 2026 SCHEDULE 13G/A GordonMD Long Biased Master Fund LP 12.1% 10,024,909 View
Jul 02, 2026 SCHEDULE 13G/A GordonMD Long Biased GP LLC 12.1% 10,024,909 View
Jul 02, 2026 SCHEDULE 13G/A Craig D. Gordon 12.1% 10,024,909 View
Feb 09, 2026 SCHEDULE 13G/A Laurion Capital Management LP 7.72% 4,796,479 View
Feb 09, 2026 SCHEDULE 13G/A Benjamin Alexander Smith 7.72% 4,796,479 View
Feb 09, 2026 SCHEDULE 13G/A Janaka Sheehan Maduraperuma 7.72% 4,796,479 View
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G. Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F). Amendments (/A) can repeat the same holder over time, so rows should not be summed. Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.